Minocycline + placebo

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Spinal Cord Injuries

Conditions

Spinal Cord Injuries

Trial Timeline

Jun 1, 2004 → Aug 1, 2010

About Minocycline + placebo

Minocycline + placebo is a phase 1/2 stage product being developed by Brain Biotech for Spinal Cord Injuries. The current trial status is completed. This product is registered under clinical trial identifier NCT00559494. Target conditions include Spinal Cord Injuries.

What happened to similar drugs?

7 of 20 similar drugs in Spinal Cord Injuries were approved

Approved (7) Terminated (1) Active (12)
🔄Ropivacaine + BupivacaineAstraZenecaPhase 3
🔄onasemnogene abeparvovecNovartisPhase 3

Hype Score Breakdown

Clinical
9
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00559494Phase 1/2Completed

Competing Products

20 competing products in Spinal Cord Injuries

See all competitors
ProductCompanyStageHype Score
SUN13837 injection + PlaceboDaiichi SankyoPhase 2
35
Placebo + Reldesemtiv 150 mg + Reldesemtiv 450 mgAstellas PharmaPhase 2
35
Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor CellsSun PharmaceuticalPhase 2
42
Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor CellsSun PharmaceuticalPhase 1
36
ElezanumabAbbViePre-clinical
30
Elezanumab + PlaceboAbbViePhase 2
35
Ropivacaine + BupivacaineAstraZenecaPhase 3
40
Onasemnogene Abeparvovec-xioiNovartisPhase 1
21
ZolgensmaNovartisPre-clinical
33
BVS857 + PlaceboNovartisPhase 2
35
AVXS-101NovartisPhase 1
29
Onasemnogene Abeparvovec-xioiNovartisPhase 3
44
Onasemnogene Abeparvovec-brveNovartisApproved
50
Onasemnogene Abeparvovec-xioiNovartisPre-clinical
30
Onasemnogene Abeparvovec-xioiNovartisPhase 3
40
branaplamNovartisPhase 1/2
32
Onasemnogene Abeparvovec-xioiNovartisPhase 3
40
onasemnogene abeparvovecNovartisPhase 3
47
onasemnogene abeparvovec-xioiNovartisPhase 3
40
RisdiplamRochePhase 1
29